We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Specific Cytokines Are Significant Biomarkers for AML

By LabMedica International staff writers
Posted on 16 Oct 2019
Acute myeloid leukemia is a hematopoietic neoplasm derived from early progenitor myeloid cells; it is characterized by clonal expansion of myeloblasts, which are immature myeloid progenitors that accumulate in the bone marrow (BM).

Immune system impairment and immunetolerance were reported in patients with acute myeloid leukemia. More...
T cells are the most active part of the immune system, nevertheless they were found to be functionally and numerically defective in acute myeloid leukemia. Interleukin-27 (IL27) and IL35 are regulatory T cells (T-regs) related cytokines; they may be involved in eukemogenesis of acute myeloid leukemia (AML).

Scientists at Sohag University (Sohag, Egypt) recruited 70 newly diagnosed patients with primary AML and 30 matched healthy volunteers. The diagnosis of AML in the patients was made using Leishman-stained peripheral blood smears; Bone marrow (BM) aspirates or occasionally trephine biopsy; Cytochemical staining of BM specimens using myeloperoxidase (MPO), esterase and periodic acid Schiff; and immunophenotyping (IPT): monoclonal antibodies (MoAb) used for staining of blast cells were labeled with fluorescein isothiocyanate, phycoerythrin.

Serum was obtained from plain blood sample tubes that were kept at −80 °C by centrifugation. Serum levels of IL-27 and IL-35 were measured by enzyme-linked immunosorbent assay (ELISA), for both patients and controls, using the commercially available kits. Absorbance was recorded at 495 nm, IL-27 assay range was 31.25–2,000 pg/mL, and IL-35 assay range was 15.63–1,000 pg/mL. The median age of the study patients was 36 years and the range was 18–80 years. Females comprised 52.9% of the patient group.

The scientists reported that significantly higher levels of IL27 and IL35 in AML patients compared with the control subjects, with median values of 77 and 51 pg/mL compared to 37 and 22.2 pg/mL, respectively. The correlations between serum levels of IL27 and IL3 in AML patients, revealed a significant positive correlation between IL27 with, white blood cell (WBCs) count, peripheral blasts percent and myeloperoxidase (MPO) positivity. However, IL35 levels showed a significant negative correlation with platelets count and significant positive correlations with age, CD45, HLA-DR and CD34.

The authors concluded that their study demonstrated that IL27 and IL35 could identify AML patients from healthy subjects, and their overexpression denotes poor prognosis. Based on the simplicity and wide availability of their detection technique they recommended the inclusion of IL27 and IL35 in the diagnostic/prognostic workup of AML. The study was published on October 1, 2019, in the Journal of Blood Medicine.

Related Links:
Sohag University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.